口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价

doi:10.19438/j.cjoms.2017.02.010

中国口腔颌面外科杂志 ›› 2017, Vol. 15 ›› Issue (2): 147-152.doi: 10.19438/j.cjoms.2017.02.010

口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价

赵志国, 潘遥, 杨东升, 张力平

中国医科大学附属盛京医院口腔颌面外科,辽宁沈阳 110004

收稿日期:2016-04-29 出版日期:2017-03-20 发布日期:2017-04-13
通讯作者: 张力平,E-mail:471535881@qq.com
作者简介:赵志国（1980-）,男,硕士,主治医师,E-mail: zhaozg@sj-hospital.org

Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses

ZHAO Zhi-guo, PAN Yao, YANG Dong-sheng, ZHANG Li-ping

Department of Oral and Maxillofacial Surgery, Shengjing Hospital of China Medical University. Shenyang 110004, Liaoning Province, China

Received:2016-04-29 Online:2017-03-20 Published:2017-04-13
Contact: 辽宁省科学技术计划（2011225020）

摘要/Abstract

摘要： 目的评价口服普萘洛尔治疗婴幼儿鼻部血管瘤的临床疗效和安全性。方法 2013年3月—2015年3月,对确诊为婴幼儿鼻部血管瘤的29例患儿采用口服普萘洛尔2.0 mg/（kg·d）治疗,分2次口服。每3~4周复诊1次,定期拍照,动态观察血管瘤的大小、质地、颜色变化,随时处理治疗过程中的不良反应,根据Achauer 疗效判定标准进行疗效评价。结果 29例患儿平均口服普萘洛尔6个月。疗效Ⅰ级（差）0例,Ⅱ级（中）2例,Ⅲ级（好）9例,Ⅳ级（优）18例;2例患儿出现轻度腹泻,2例出现睡眠障碍,未发生严重不良反应。结论口服普萘洛尔治疗婴幼儿鼻部血管瘤起效快,疗效好,不良反应轻微,可作为首选方法。

关键词: 血管瘤, 普萘洛尔, 婴幼儿

Abstract: PURPOSE : To estimate the efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses. METHODS : From March, 2013 to March, 2015, 29 infantile hemangiomas in the noses were treated with oral propranolol at a dose of 2.0 mg/(kg·d), divided into 2 times. The changes of the tumor size, texture and color were monitored and recorded at a regular interval. The adverse reactions after medication were observed and managed accordingly. The efficacy was evaluated using Achauer's system. RESULTS : The average mediation duration was 6 months. The overall response was gradeⅡ in 2 patients, grade Ⅲ in 9 patients, grade Ⅳ in 18 patients. Adverse reactions were observed in 2 patients, including mild diarrhea and sleep disturbance. CONCLUSION S: Oral propranolol is effective and safe for the treatment of infantile hemangiomas in the noses, and the adverse reaction is minimal.

Key words: Hemangioma, Propranolol, Infant

中图分类号:

R732.2

赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 147-152.

ZHAO Zhi-guo, PAN Yao, YANG Dong-sheng, ZHANG Li-ping. Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses[J]. China J Oral Maxillofac Surg, 2017, 15(2): 147-152.

参考文献

[1] Shah S, Frieden IJ. Treatment of infantile hemangiomas with Beta-blockers: a review [J].Skin Therapy Lett, 2013, 18(6): 5-7.
[2] 郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变 [J].中国口腔颌面外科杂志, 2012, 10(2): 163-164.
[3] 张继斌, 刘军, 陈松龄. 婴幼儿腮腺血管瘤的治疗探讨 [J].口腔医学, 2014, 34(7): 555-557.
[4] Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas[J]. Arch Otolaryngol Head Neck Surg, 2011, 137(5): 471-478.
[5] Bruckner AL, Frienden IJ. Hemangiomas of infancy[J]. J Am Acad Dermatol, 2003, 48(4): 477-493.
[6] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[7] Chang LC, Haggstrom AN, Drolet BA, et al. Growth characterisities of infantile hemangiomas: implications for management [J].Pediatrics, 2008, 122(2): 360-367.
[8] 王绪凯.脉管性疾病的治疗 [J].中国实用口腔科杂志, 2009, 2(5): 280-282.
[9] Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of literature [J]. Int J Pediatr Otorhinolaryngol, 2010, 74(4): 338-342.
[10] Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action [J]. Br J Dermatol, 2010, 163(2): 269-274.
[11] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J].N Engl J Med, 2008, 358(24): 2649-2651.
[12] Hogeling M, Adams S, Wargon O. A randomized controlled trial of opranolol for infantile hemangiomas [J]. Pediatrics, 2011, 128(2): e259-266.
[13] Hermans DJ, Bauland CG, Zweegers J, et al. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions [J].Br J Dermatol, 2013, 168(4): 837-843.
[14] Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol [J]. Br J Dermatol, 2013, 168(1): 222-224.
[15] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatrics, 2013, 131(1): 128-140.
[16] 郑家伟, 张凌, 陈正岗. 普萘洛尔治疗婴幼儿血管瘤专家共识[J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.

口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价

Efficacy and safety of oral propranolol for the treatment of infantile hemangiomas in the noses

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[2]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[3]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[4]	张瑛, 周加倩, 康华. 七氟烷诱导麻醉下喉罩与气管插管在婴幼儿颌面部血管畸形介入手术中的效果比较[J]. 中国口腔颌面外科杂志, 2022, 20(3): 277-281.
[5]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[6]	胡光珍, 王新颖, 龚毓宾, 董长宪. 66例卡-梅现象患儿术前单次大剂量快速输注血小板时机探讨[J]. 中国口腔颌面外科杂志, 2022, 20(1): 48-51.
[7]	仇琳, 李静洁, 张凌, 蒋超. 不同麻醉维持药物对长时间手术婴幼儿血清同型半胱氨酸浓度的影响[J]. 中国口腔颌面外科杂志, 2021, 19(3): 244-247.
[8]	林晓锐, 李晨曦, 张秀华. 瑞芬太尼复合氯胺酮在婴幼儿唇腭裂手术中的麻醉效果分析[J]. 中国口腔颌面外科杂志, 2021, 19(1): 45-48.
[9]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[10]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[11]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[12]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[13]	张涵恕, 刘少华, 郑家伟. 聚多卡醇治疗血管瘤及脉管畸形研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(1): 77-81.
[14]	张翀, 麦华明. 先天性血管瘤诊治进展[J]. 中国口腔颌面外科杂志, 2020, 18(1): 82-86.
[15]	林晓曦. 血管瘤和脉管畸形的诊疗进展（2018—2019）及关键性问题[J]. 中国口腔颌面外科杂志, 2019, 17(6): 486-495.